|
Press Releases
VisiGen
Receives Patent for Real-Time
Single-Molecule DNA Sequencing
HOUSTON, TX - February 15, 2008 - VisiGen
Biotechnologies, Inc., was awarded US Patent No.
7,329,492, "Methods for Real-time Single Molecule
Sequence Determination," European and Australian
counterparts have also recently issued. VisiGen's
President, Dr. Susan Hardin, Ph.D. said, "We have the
real path to the $1,000 human genome." VisiGen's
sequencing methodology can be used to sequence the
genome of a human or any other life form. [read
the entire release... or
Word Doc
296
KB]
Dr. Susan Hardin, President and CEO of VisiGen
Biotechnologies Inc. short-listed for 2006 World
Technology Award
NEW YORK, NY - October 6, 2006 - The World Technology Network (WTN) announced today
that Dr. Susan Hardin, from
VisiGen Biotechnologies Inc., has
been short-listed as a nominee for a 2006 World Technology Award, presented by
the World Technology Network, in association with the New York Stock Exchange
(NYSE), Dow Chemical, TIME magazine and CNN, among others.
Susan Hardin is eligible to be
selected as the Winner of the 2006 World Technology Award for Health and
Medicine. [read more...or
Word Doc
304
KB, or
PDF
Doc 148 KB]
Applied Biosystems Completes Equity Investment in VisiGen
Biotechnologies
FOSTER CITY, CA and HOUSTON, TX — December 8, 2005 — Applied Biosystems Group
(NYSE:ABI), an Applera Corporation business, announced today that it has
completed its previously announced equity investment in privately held VisiGen
Biotechnologies, a next-generation sequencing technology company. Concurrent
with its investment, Applied Biosystems also entered into a scientific
collaboration agreement with VisiGen. Financial terms of the transactions were
not disclosed.
The VisiGen investment is part of Applied Biosystems’ strategy of maintaining
its leadership position in DNA sequencing by complementing its internal
investments in new and existing sequencing technologies with promising
next-generation approaches. [read more...]
SeqWright to Make Follow-on Investment in VisiGen Biotechnologies
Houston — November 2, 2005 — SeqWright Inc. and VisiGen Biotechnologies,
Inc., announced today that SeqWright has signed a definitive agreement to make a
follow-on equity investment in privately held VisiGen, a next generation
sequencing technology company. Financial terms of the transaction were not
disclosed. [read
more...]
Applied Biosystems to Invest in VisiGen Biotechnologies
FOSTER CITY, Calif. & HOUSTON—(BUSINESS WIRE)—Oct. 26, 2005—Applied
Biosystems Group (NYSE:ABI - News), an Applera Corporation business, and VisiGen
Biotechnologies, Inc., announced today that Applied Biosystems has signed a
definitive agreement to make an equity investment in privately held VisiGen, a
next-generation sequencing technology company, and to enter into a scientific
collaboration agreement with VisiGen concurrent with the closing of the
investment. The investment and the collaboration are subject to closing
conditions specified in the investment agreement, including VisiGen’s receipt of
an additional investment from SeqWright, Inc., an existing VisiGen shareholder,
and other conditions that are customary for a transaction of this type. The
companies expect that Applied Biosystems’ investment will be made and the
collaboration commenced by calendar year end. Financial terms of the
transactions were not disclosed. [read
more ...]
VisiGen Awarded NIH SBIR for Biomolecule Labeling Method
(Houston, TX) VisiGen Biotechnologies, Inc., (VisiGen), announces the award
of a Phase 1 SBIR grant from the National Institute of Health, National
Institute of General Medical Sciences, to develop a novel method for labeling
DNA, RNA and proteins. This method may be used to directly label RNA for
microarray experiments at a fraction of the cost of current labeling
methods. [read
more... or
Word Doc
88
KB, or
PDF
Doc 117 KB]
NIH Awarded VisiGen $4.2 Million
BETHESDA, Md., Mon., Aug. 8, 2005 — NHGRI’s “Revolutionary Genome Sequencing
Technologies” grants have as their goal the development of breakthrough
technologies that will enable a human-sized genome to be sequenced for $1,000 or
less. [read
more ...]
Susan H. Hardin, Ph.D.,
VisiGen Biotechnologies,
Inc., Houston.
$4.2 million (3 years)
“Real-Time DNA Sequencing”
This group is developing a sequencing system in which polymerase (an enzyme
used to synthesize DNA molecules) and nucleotides act together as direct
molecular sensors of DNA base identity. The key to the system is the interaction
between a fluorescent polymerase and the nucleotide, which emits a signature
detectable in real-time. [read
more... or
Word Doc
88
KB, or
PDF Doc 117 KB]
VisiGen Enters into Strategic Partnership with SeqWright
Houston, TX — November 7, 2004 — VisiGen Biotechnologies, Inc., developer of
single molecule DNA sequencing technologies, announced today a strategic
alliance with SeqWright, Inc., a provider of DNA sequencing and other molecular
biology services. The alliance involves transfer of VisiGen stock and an
undisclosed cash payment from SeqWright. The move comes as VisiGen demonstrates
proof of principle of its proprietary methods. [read
more...]
Email:
info@visigenbio.com
|